# DUSP2

## Overview
DUSP2, or dual specificity phosphatase 2, is a gene that encodes a protein belonging to the dual-specificity phosphatase family, which is involved in the regulation of mitogen-activated protein kinase (MAPK) signaling pathways. The protein encoded by DUSP2, also known as PAC1, functions primarily as a nuclear phosphatase that inactivates key MAPKs such as ERK1/2 and p38 MAPK, thereby playing a critical role in controlling cellular processes like proliferation, differentiation, and apoptosis (Haag2016The; Lang2019DualSpecificity). DUSP2 is also implicated in immune regulation, particularly in lymphocytes, where it modulates inflammatory signaling and Th17 cell lineage commitment (Lang2019DualSpecificity). Clinically, alterations in DUSP2 expression have been associated with various cancers, suggesting its potential role as a tumor suppressor and a biomarker for cancer prognosis (Liu2019Expression; Yin2019Loss).

## Function
DUSP2, also known as PAC1, is a dual-specificity phosphatase that plays a significant role in regulating mitogen-activated protein kinase (MAPK) pathways, specifically by inactivating ERK1/2 and p38 MAPK. These pathways are crucial for cell proliferation, differentiation, and apoptosis, and DUSP2 acts as a negative regulator, helping to control cell growth and maintain cellular homeostasis (Haag2016The). 

In healthy human cells, DUSP2 is involved in regulating apoptosis through interactions with the p53 and E2F1 pathways, which are essential for preventing uncontrolled cell growth (Haag2016The). DUSP2 is primarily active in the nucleus, where it modulates MAPK activity to maintain cellular balance (Lang2019DualSpecificity). 

DUSP2 also plays a role in immune regulation. It is highly expressed in lymphocytes following activation and acts as a positive regulator of inflammatory cell signaling and effector functions. It is involved in the dephosphorylation of STAT3, thereby negatively regulating STAT3 signaling during Th17 cell lineage commitment (Lang2019DualSpecificity). This regulatory function is crucial for controlling the intensity and duration of immune responses (Lang2019DualSpecificity).

## Clinical Significance
Alterations in the expression of the DUSP2 gene have been implicated in various cancers. In bladder cancer, DUSP2 expression is significantly lower in cancerous tissues compared to normal tissues, and its downregulation is associated with tumor progression and poor prognosis. This suggests that DUSP2 could serve as a biomarker for bladder cancer progression and prognosis (Yin2019Loss). In colorectal cancer, DUSP2 expression is differentially regulated, with higher levels in left-sided colon cancer compared to right-sided colon cancer. The loss of DUSP2 function in colorectal cancer is linked to prolonged ERK activation, contributing to drug resistance and tumorigenesis (Dong2018Differential).

DUSP2 is also downregulated in serous ovarian carcinoma, where its reduced expression correlates with advanced tumor stage and poor patient survival. This downregulation is considered an independent risk factor for survival, highlighting its potential role as a tumor suppressor (Liu2019Expression). In various cancers, including acute leukemia and ovarian serous carcinoma, DUSP2 downregulation is not due to hypermethylation but is inhibited by hypoxia-inducible factor 1-alpha (HIF-1α), leading to increased chemoresistance and malignancy (Lin2011Suppression).

## Interactions
DUSP2 interacts with atypical MAP kinases ERK3 and ERK4 in a kinase interaction motif (KIM)-dependent manner, both in vitro and in vivo. This interaction does not require DUSP2's catalytic activity, as catalytically inactive mutants still bind to these kinases. The interaction leads to the relocalization of ERK3 and ERK4 from the nucleus to the cytoplasm, similar to their interaction with the substrate MK5 (Perander2017Regulation). DUSP2 also influences the stability of ERK4, which is dependent on the integrity of the KIM motif within DUSP2. A KIM mutant of DUSP2 does not stabilize upon expression of ERK4, highlighting the importance of this motif (Perander2017Regulation).

DUSP2 binds strongly to ERK3 and ERK4, more so than to ERK2, resulting in the dephosphorylation of the serine phospho-acceptor residue within their activation loops. This interaction is dependent on the common docking (CD) domain and the KIM within DUSP2 (Perander2017Regulation). DUSP2 also suppresses ERK3 or ERK4-dependent phosphorylation of MK5, indicating a regulatory role in the Pak-ERK3/ERK4-MK5 signaling axis (Perander2017Regulation). These interactions suggest that DUSP2 plays a significant role in modulating MAPK signaling pathways, potentially linking them to inflammatory responses (Perander2017Regulation).


## References


[1. (Dong2018Differential) Wenjie Dong, Na Li, Xiufeng Pei, and Xinai Wu. Differential expression of dusp2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer. Oncology Letters, January 2018. URL: http://dx.doi.org/10.3892/ol.2018.7881, doi:10.3892/ol.2018.7881. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2018.7881)

[2. (Lin2011Suppression) Shih-Chieh Lin, Chun-Wei Chien, Jenq-Chang Lee, Yi-Chun Yeh, Keng-Fu Hsu, Yen-Yu Lai, Shao-Chieh Lin, and Shaw-Jenq Tsai. Suppression of dual-specificity phosphatase–2 by hypoxia increases chemoresistance and malignancy in human cancer cells. Journal of Clinical Investigation, 121(5):1905–1916, May 2011. URL: http://dx.doi.org/10.1172/jci44362, doi:10.1172/jci44362. This article has 74 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci44362)

[3. (Haag2016The) Tanja Haag, Antje M. Richter, Martin B. Schneider, Adriana P. Jiménez, and Reinhard H. Dammann. The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms. BMC Cancer, February 2016. URL: http://dx.doi.org/10.1186/s12885-016-2087-6, doi:10.1186/s12885-016-2087-6. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-016-2087-6)

[4. (Liu2019Expression) Wei Liu, Xiaomin Tian, Xue Ding, and Leiying Zhang. Expression of dual-specificity phosphatase 2 (dusp2) in patients with serous ovarian carcinoma and in skov3 and ovcar3 cells in vitro. Medical Science Monitor, 25:10180–10189, December 2019. URL: http://dx.doi.org/10.12659/msm.919089, doi:10.12659/msm.919089. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.12659/msm.919089)

[5. (Perander2017Regulation) Maria Perander, Rania Al-Mahdi, Thomas C. Jensen, Jennifer A. L. Nunn, Hanne Kildalsen, Bjarne Johansen, Mads Gabrielsen, Stephen M. Keyse, and Ole-Morten Seternes. Regulation of atypical map kinases erk3 and erk4 by the phosphatase dusp2. Scientific Reports, March 2017. URL: http://dx.doi.org/10.1038/srep43471, doi:10.1038/srep43471. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep43471)

[6. (Yin2019Loss) Hubin Yin, Weiyang He, Yunhai Li, Ning Xu, Xin Zhu, Yong Lin, and Xin Gou. Loss of dusp2 predicts a poor prognosis in patients with bladder cancer. Human Pathology, 85:152–161, March 2019. URL: http://dx.doi.org/10.1016/j.humpath.2018.11.007, doi:10.1016/j.humpath.2018.11.007. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.humpath.2018.11.007)

[7. (Lang2019DualSpecificity) Roland Lang and Faizal Raffi. Dual-specificity phosphatases in immunity and infection: an update. International Journal of Molecular Sciences, 20(11):2710, June 2019. URL: http://dx.doi.org/10.3390/ijms20112710, doi:10.3390/ijms20112710. This article has 95 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms20112710)